Public Sector Pension Investment Board lessened its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 4.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,042,062 shares of the company’s stock after selling 46,754 shares during the quarter. AbbVie accounts for approximately 0.6% of Public Sector Pension Investment Board’s investment portfolio, making the stock its 25th biggest position. Public Sector Pension Investment Board owned about 0.06% of AbbVie worth $285,541,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of ABBV. FreeGulliver LLC increased its position in AbbVie by 12.9% during the 3rd quarter. FreeGulliver LLC now owns 1,281 shares of the company’s stock worth $335,000 after purchasing an additional 146 shares in the last quarter. BCGM Wealth Management LLC bought a new position in AbbVie in the 3rd quarter valued at approximately $239,000. Garrison Point Advisors LLC lifted its stake in AbbVie by 5.2% in the 3rd quarter. Garrison Point Advisors LLC now owns 3,172 shares of the company’s stock valued at $830,000 after purchasing an additional 156 shares during the last quarter. Cibc World Market Inc. boosted its position in AbbVie by 22.4% in the third quarter. Cibc World Market Inc. now owns 742,097 shares of the company’s stock valued at $194,125,000 after buying an additional 135,914 shares in the last quarter. Finally, Cullen Capital Management LLC boosted its position in AbbVie by 15.0% in the third quarter. Cullen Capital Management LLC now owns 8,222 shares of the company’s stock valued at $2,151,000 after buying an additional 1,070 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.
Wall Street Analyst Weigh In
ABBV has been the topic of a number of research reports. HSBC boosted their target price on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Scotiabank increased their price target on AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Weiss Ratings raised AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Canaccord Genuity Group raised their price objective on AbbVie from $290.00 to $338.00 and gave the company a “buy” rating in a report on Monday, November 2nd. Finally, UBS Group boosted their price objective on AbbVie from $275.00 to $295.00 and gave the stock a “neutral” rating in a research report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $297.85.
Get Our Latest Analysis on AbbVie
AbbVie Price Performance
Shares of NYSE ABBV opened at $292.40 on Wednesday. The company has a 50 day simple moving average of $277.14 and a 200 day simple moving average of $241.64. The firm has a market cap of $516.85 billion, a PE ratio of 50.33, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $302.93.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same period last year, the company earned $1.86 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. As a group, research analysts anticipate that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.
AbbVie Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. The ex-dividend date of this dividend is Friday, January 15th. This is an increase from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. AbbVie’s payout ratio is 119.10%.
Insider Activity
In other news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the transaction, the executive vice president owned 83,171 shares in the company, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.
AbbVie News Roundup
Here’s some of the latest news about ABBV:
- Positive Sentiment: AbbVie’s neuroscience franchise delivered 19.5% operational sales growth in Q3, and the company raised its 2026 segment sales outlook to $13 billion. That suggests momentum in a key growth area. Article: How Did AbbVie’s Neuroscience Franchise Perform in Q3?
- Positive Sentiment: Barclays raised its price target to $335 from $325 and maintained an Overweight rating, signaling continued analyst confidence in AbbVie’s outlook. Article: AbbVie Is Up 27% in a Year. Barclays Sees Another 14%
- Positive Sentiment: New AI drug-discovery work with Iambic and expanded rights to Brise’s preclinical migraine programs broaden AbbVie’s research pipeline, particularly in neuroscience. These efforts may support future growth, though they are early-stage. Article: AbbVie Expands Its Pipeline With New AI Drug Discovery Partnerships
AbbVie Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Read More
- Five stocks we like better than AbbVie
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
